Cromos Pharma supporting lung cancer clinical trials
November is Lung Cancer Awareness Month. Lung cancer is the most common cause of cancer death worldwide making up almost 25% of all cancer deaths. Every year, more people die of lung cancer than of colon, breast, and prostate cancers combined. In recent years, clinical research has led to significant breakthroughs in the treatment of lung cancer, giving hope to millions of patients worldwide. However, there is still some way to go to reduce deaths from this cancer. Cromos Pharma is proud to play its part in supporting clinical trials to test and develop innovative drugs and interventions for lung cancer.
Lung cancer facts
Smoking is the most common cause of lung cancer. Other risk factors include genetic or familial history, inhalation of second-hand smoke, and radiation treatment for breast or chest cancer. Exposure to toxins such as tar, asbestos, nickel, and chromium in the workplace and exposure to radon can also cause lung cancer.
There are two main type of lung cancer – small cell lung cancer and the most common form – non-small cell lung cancer.
The signs and symptoms of lung cancer are:
- A cough that doesn’t go away or a change in a long-term cough
- Feeling short of breath or wheezing
- Repeated chest infections that won’t go away even after antibiotics
- Coughing up blood-stained phlegm
- Pain in your chest, especially when you cough or breathe in
- Feeling more tired than usual and/or unexplained weight loss
- Hoarse voice, problems swallowing or swelling in the face or neck
As with all cancers, getting tested and diagnosed as early as possible increases your chances of survival.
Cromos Pharma’s oncology track record
Since our establishment in 2004, Cromos Pharma has conducted dozens of oncology clinical studies involving the participation of thousands of patients across our regions including Central and Eastern Europe. These studies have focused on a range of areas from finding innovative targeted therapies, to biosimilar and generic studies, aimed at offering wider access to novel treatments.
A tailored and flexible approach to oncology studies
Cromos Pharma offers a flexible oncology model to international sponsors, focused on optimized study design combined with rapid patient enrollment, to accelerate high quality data results. The Cromos Pharma approach focuses on:
- Optimized study design
- In-depth regulatory expertise across our regions
- Faster start-up timelines
- Rapid patient enrollment
- High quality data
ABOUT CROMOS PHARMA
Cromos Pharma is a US-based international contract research organization with 16 years’ experience in delivering fully integrated clinical research solutions, in all trial phases, across a wide range of therapeutic areas. Our expert team boasts wide-ranging expertise in study design, medical writing, regulatory affairs, site management, patient recruitment and data management.
From studies in biosimilars and generics to successfully managing oncology, neurology, and dermatology clinical trials, our team provides full service solutions to international pharma and biotech in high recruiting regions, with high quality data assured.
Established in 2004, Cromos Pharma has strong regional experience in Central and Eastern Europe, supported by an extensive network of offices. Its international HQ is in Portland, Oregon, USA.